

## SUPPLEMENTARY INFORMATION

### ***OPA1* gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.**

Emmanuelle Sarzi<sup>1</sup>, Marie Seveno<sup>1</sup>, Camille Piro-Mégy<sup>1</sup>, Lucie Elziere<sup>1</sup>, Mélanie Quilès<sup>1</sup>, Marie Péquignot<sup>1</sup>, Agnès Müller<sup>1,2</sup>, Christian P Hamel<sup>1,3</sup>, Guy Lenaers<sup>1,4\*</sup>, Cécile Delettre<sup>1\*</sup>.

<sup>1</sup>UMR INSERM U1051/ Université Montpellier - Institut des Neurosciences de Montpellier, 34091 Montpellier, France.

<sup>2</sup>Université de Montpellier - Faculté de Pharmacie-34093 Montpellier, France

<sup>3</sup>Affections sensorielles génétiques, Hôpital Gui de Chauliac, Montpellier, France

<sup>4</sup>PREMMI, UMR CNRS 6015, INSERM U1083, Université d'Angers, France

\* Last authors contributed equally to this work

Corresponding author : Dr Emmanuelle Sarzi, PhD, Institut des Neurosciences de Montpellier, Hôpital St Eloi – 34091 Montpellier – France, e-mail: emmanuelle.sarzi@inserm.fr

## SUPPLEMENTARY FIGURES

Figure S1




Figure S1: Control of the *HsOPA1* gene and protein expression in the NIH3T3 mouse strain. (A) real-time quantitative PCR of murine *Opa1* and *HsOPA1* transcripts reported to the L27 gene expression ( $n=3$ ). (B) Western blot using a home-made-OPA1 and actin antibodies.

**Figure S2**




Figure S2: Quantification of GFP and Brn3a staining on whole-mount retina. Data were expressed as the mean  $\pm$  SEM.

## **SUPPLEMENTARY MATERIAL AND METHOD**

### *NIH3T3 transfections and control of the HsOPA1 protein expression*

NIH3T3 cells were cultured in complete culture medium (Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum and 100 units/ml penicillin/streptomycin, Invitrogen) and maintained at 37 °C in a humidified 5% CO<sub>2</sub> atmosphere. Cells were seeded at a concentration of a  $2 \times 10^5$  into 6-well plates. Transient transfections with the pGG2-pCMV-HsOPA1 construction were performed using Lipofectamine 2 000 in Optimem (Invitrogen) according to the manufacturer's protocol. Empty pGG2 vector was used as control. Twenty-four hours after transfection, cells were harvested and protein were extracted in RIPA buffer (50 mM Tris-HCl, pH8.0, 150 mM sodium chloride, 1% NP-40, 0.1% SDS, and 0.5% sodium

deoxycholate). Proteins (40 µg) were separated by 7.5% SDS-PAGE and transferred onto a nitrocellulose membrane (Bio-Rad, Hertfordshire, UK). Primary antibodies against OPA1 protein (home-made antibody) and Actin (1:5000, Sigma-Aldrich) were visualized using horseradish peroxidase-conjugated secondary antibody.